Reasons for Not Seeking Hepatitis C Treatment among People Who Inject Drugs

References

• Alavi, M., Grebely, J., Micallef, M., Dunlop, A. J., Balcomb, A. C., Day, C. A., Treloar, C., Bath, N., Haber, P. S., Dore, G. J, & Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) Study Group. (2013). Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS Study. Clinical Infectious Diseases, 57(suppl_2), S62–S69. https://doi.org/10.1093/cid/cit305
   PubMedGoogle Scholar
• Alberti, A., Noventa, F., Benvegnù, L., Boccato, S., & Gatta, A. (2002). Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Annals of Internal Medicine, 137(12), 961–964. https://doi.org/10.7326/0003-4819-137-12-200212170-00009
   Google Scholar
• Artenie, A. A., Zang, G., Daniel, M., Fortier, E., Jutras-Aswad, D., Puzhko, S., & Bruneau, J. (2017). Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. The International Journal on Drug Policy, 47, 239–243. https://doi.org/10.1016/j.drugpo.2017.05.033
   PubMed Web of Science ®Google Scholar
• Batchelder, A. W., Cockerham-Colas, L., Peyser, D., Reynoso, S. P., Soloway, I., & Litwin, A. H. (2017). Perceived benefits of the hepatitis C peer educators: A qualitative investigation. Harm Reduction Journal, 14(1), 67. https://doi.org/10.1186/s12954-017-0192-8
   PubMedGoogle Scholar
• Bedford, A., & Deary, I. J. (1999). The delusions-symptoms-states inventory (DSSI): Construction, applications and structural analyses. Personality and Individual Differences, 26(3), 397–424. https://doi.org/10.1016/S0191-8869(98)00118-4
   Web of Science ®Google Scholar
• Bruggmann, P. (2012). Accessing hepatitis C patients who are difficult to reach: It is time to overcome barriers. Journal of Viral Hepatitis, 19(12), 829–835. https://doi.org/10.1111/jvh.12008
   PubMed Web of Science ®Google Scholar
• Butler, K., Larney, S., Day, C. A., & Burns, L. (2019). Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. Drug and Alcohol Review, 38(3), 264–269. https://doi.org/10.1111/dar.12883
   PubMed Web of Science ®Google Scholar
• Crowley, D., Cullen, W., Laird, E., Lambert John, S., Mc Hugh, T., Murphy, C., & Van Hout Marie, C. (2017). Exploring patient characteristics and barriers to hepatitis C treatment in patients on opioid substitution treatment attending a community based fibro-scanning clinic. Journal of Translational Internal Medicine, 5(2), 112–119. https://doi.org/10.1515/jtim-2017-0017
   PubMed Web of Science ®Google Scholar
• Doab, A., Treloar, C., & Dore, G. J. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases, 40(Suppl 5), S313–S320. https://doi.org/10.1086/427446
   PubMed Web of Science ®Google Scholar
• Evon, D. M., Simpson, K. M., Esserman, D., Verma, A., Smith, S., & Fried, M. W. (2010). Barriers to accessing care in patients with chronic hepatitis C: The impact of depression. Alimentary Pharmacology & Therapeutics, 32(9), 1163–1173. https://doi.org/10.1111/j.1365-2036.2010.04460.x
   PubMed Web of Science ®Google Scholar
• Grebely, J., Bryant, J., Hull, P., Hopwood, M., Lavis, Y., Dore, G. J., & Treloar, C. (2011). Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales. Journal of Viral Hepatitis, 18(4), e104–e116. https://doi.org/10.1111/j.1365-2893.2010.01370.x
   PubMed Web of Science ®Google Scholar
• Grebely, J., Dore, G. J., Morin, S., Rockstroh, J. K., & Klein, M. B. (2017). Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? Journal of the International AIDS Society, 20(1), 22146. https://doi.org/10.7448/ias.20.1.22146
   PubMedGoogle Scholar
• Harris, M., Bonnington, O., Harrison, G., Hickman, M., & Irving, W. (2018). Understanding hepatitis C intervention success-Qualitative findings from the HepCATT study. Journal of Viral Hepatitis, 25(7), 762–770. https://doi.org/10.1111/jvh.12869
   PubMed Web of Science ®Google Scholar
• Heard, S., I. J., Geddes, L., & Maher, L. (2018). Australian needle syringe program survey national data report 2013-2017: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Kirby Institute, UNSW Sydney.
   Google Scholar
• Heard, S., I. J., Kwon, J. A., & Maher, L. (2018). Needle syringe program national minimum data collection: National data report 2018. Kirby Institute, UNSW Sydney.
   Google Scholar
• Henderson, C., Madden, A., & Kelsall, J. (2017). 'Beyond the willing & the waiting' - The role of peer-based approaches in hepatitis C diagnosis & treatment. The International Journal on Drug Policy, 50, 111–115. https://doi.org/10.1016/j.drugpo.2017.08.004
   PubMed Web of Science ®Google Scholar
• Iversen, J., Dore, G. J., Catlett, B., Cunningham, P., Grebely, J., & Maher, L. (2019). Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia. Journal of Hepatology, 70(1), 33–39. https://doi.org/10.1016/j.jhep.2018.09.030
   PubMed Web of Science ®Google Scholar
• Iversen, J., Grebely, J., Topp, L., Wand, H., Dore, G., & Maher, L. (2014). Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999-2011. Journal of Viral Hepatitis, 21(3), 198–207. https://doi.org/10.1111/jvh.12129
   PubMed Web of Science ®Google Scholar
• Jain, A. K. (2010). Data clustering: 50 years beyond K-means. Pattern Recognition Letters, 31(8), 651–666. https://doi.org/10.1016/j.patrec.2009.09.011
   Web of Science ®Google Scholar
• Lamoury, F. M. J., Bajis, S., Hajarizadeh, B., Marshall, A. D., Martinello, M., Ivanova, E., Catlett, B., Mowat, Y., Marks, P., Amin, J., Smith, J., Ezard, N., Cock, V., Hayllar, J., Persing, D. H., Kleman, M., Cunningham, P., Dore, G. J., Applegate, T. L., & Grebely, J. (2018). Evaluation of the Xpert HCV viral load finger-stick point-of-care assay. The Journal of Infectious Diseases, 217(12), 1889–1896. https://doi.org/10.1093/infdis/jiy114
   PubMed Web of Science ®Google Scholar
• Madden, A., Hopwood, M., Neale, J., & Treloar, C. (2018). Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLoS One, 13(11), e0207226 https://doi.org/10.1371/journal.pone.0207226
   PubMed Web of Science ®Google Scholar
• Makarenko, I., Artenie, A., Hoj, S., Minoyan, N., Jacka, B., Zang, G., Barlett, G., Jutras-Aswad, D., Martel-Laferriere, V., & Bruneau, J. (2019). Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs? The International Journal on Drug Policy, 72, 69–76. https://doi.org/10.1016/j.drugpo.2019.04.002
   PubMed Web of Science ®Google Scholar
• McGowan, C. E., & Fried, M. W. (2012). Barriers to hepatitis C treatment. Liver International, 32(Suppl 1), 151–156. https://doi.org/10.1111/j.1478-3231.2011.02706.x
   PubMedGoogle Scholar
• Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., Strathdee, S. A., & Thomas, D. L. (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33(3), 126–133. https://doi.org/10.1007/s10900-007-9083-3
   PubMed Web of Science ®Google Scholar
• Memedovic, S., Iversen, J., Geddes, L., & Maher, L. (2016). Australian needle syringe program survey national data report 2011-2015: Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Kirby Institute, UNSW Australia.
   Google Scholar
• Midgard, H., Hajarizadeh, B., Cunningham, E. B., Conway, B., Backmund, M., Bruggmann, P., Bruneau, J., Bourgeois, S., Dunlop, A., Foster, G. R., Hellard, M., Robaeys, G., Thurnheer, M. C., Weltman, M., Amin, J., Marks, P. S., Quiene, S., Dore, G. J., Dalgard, O., & Grebely, J. (2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. The International Journal on Drug Policy, 47, 230–238. https://doi.org/10.1016/j.drugpo.2017.05.040
   PubMed Web of Science ®Google Scholar
• Morris, L., Smirnov, A., Kvassay, A., Leslie, E., Kavanagh, R., Alexander, N., Davey, G., Williams, O., Gilks, C., & Najman, J. (2017). Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network. The International Journal on Drug Policy, 47, 216–220. https://doi.org/10.1016/j.drugpo.2017.05.056
   PubMed Web of Science ®Google Scholar
• Nguyen, P., Vutien, P., Hoang, J., Trinh, S., Le, A., Yasukawa, L. A., Weber, S., Henry, L., & Nguyen, M. H. (2017). Barriers to care for chronic hepatitis C in the direct-acting antiviral era: A single-centre experience. BMJ Open Gastroenterology, 4(1), e000181. https://doi.org/10.1136/bmjgast-2017-000181
   PubMed Web of Science ®Google Scholar
• Patel, E. U., Solomon, S. S., Mcfall, A. M., Srikrishnan, A. K., Pradeep, A., Nandagopal, P., Laeyendecker, O., Tobian, A. A. R., Thomas, D. L., Sulkowski, M. S., Kumar, M. S., & Mehta, S. H. (2018). Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India. International Journal on Drug Policy., 57, 51–60. https://doi.org/10.1016/j.drugpo.2018.03.023
   PubMed Web of Science ®Google Scholar
• Perlman, D. C., Jordan, A. E., Uuskula, A., Huong, D. T., Masson, C. L., Schackman, B. R., & Des Jarlais, D. C. (2015). An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. The International Journal on Drug Policy, 26(11), 1056–1063. https://doi.org/10.1016/j.drugpo.2015.04.015
   PubMed Web of Science ®Google Scholar
• Read, P., Lothian, R., Chronister, K., Gilliver, R., Kearley, J., Dore, G. J., & van Beek, I. (2017). Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. International Journal of Drug Policy, 47, 209–215. https://doi.org/10.1016/j.drugpo.2017.05.032
   PubMed Web of Science ®Google Scholar
• Richmond, J. A., Ellard, J., Wallace, J., Thorpe, R., Higgs, P., Hellard, M., & Thompson, A. (2018). Achieving a hepatitis C cure: A qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using the direct acting antivirals in Australia. Hepatology, Medicine and Policy, 3(1), 8. https://doi.org/10.1186/s41124-018-0036-5
   PubMedGoogle Scholar
• Socías, M. E., Karamouzian, M., Parent, S., Barletta, J., Bird, K., & Ti, L. (2019). Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. The International Journal on Drug Policy, 72, 146–159. https://doi.org/10.1016/j.drugpo.2019.05.023
   PubMed Web of Science ®Google Scholar
• Solund, C., Hallager, S., Pedersen, M. S., Fahnoe, U., Ernst, A., Krarup, H. B., Roge, B. T., Christensen, P. B., Laursen, A. L., Gerstoft, J., Belard, E., Madsen, L. G., Schonning, K., Pedersen, A. G., Bukh, J.,& Weis, N. (2018). Direct acting antiviral treatment of chronic hepatitis C in Denmark: Factors associated with and barriers to treatment initiation. Scandinavian Journal of Gastroenterology, 53(7), 849–856. https://doi.org/10.1080/00365521.2018.1467963
   PubMed Web of Science ®Google Scholar
• StataCorp. (2015). Stata statistical software: Release 14. StataCorp LP.
   Google Scholar
• Sublette, V. A., Smith, S. K., George, J., McCaffery, K., & Douglas, M. W. (2015). The Hepatitis C treatment experience: Patients' perceptions of the facilitators of and barriers to uptake, adherence and completion. Psychology & Health, 30(8), 987–1004. https://doi.org/10.1080/08870446.2015.1012195
   PubMed Web of Science ®Google Scholar
• Swan, D., Long, J., Carr, O., Flanagan, J., Irish, H., Keating, S., Keaveney, M., Lambert, J., McCormick, P. A., McKiernan, S., Moloney, J., Perry, N., & Cullen, W. (2010). Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care and STDs, 24(12), 753–762. https://doi.org/10.1089/apc.2010.0142
   PubMed Web of Science ®Google Scholar
• Treloar, C., Hull, P., Dore, G. J., & Grebely, J. (2012). Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug and Alcohol Review, 31(7), 918–924. https://doi.org/10.1111/j.1465-3362.2012.00468.x
   PubMed Web of Science ®Google Scholar
• Treloar, C., Rance, J., & Backmund, M. (2013). Understanding barriers to hepatitis C virus Care and stigmatization from a social perspective. Clinical Infectious Diseases, 57(suppl_2), S51–S55. https://doi.org/10.1093/cid/cit263
   PubMed Web of Science ®Google Scholar
• Williams, B., Howell, J., Doyle, J., Thompson, A. J., Draper, B., Layton, C., Latham, N., Bramwell, F., Membrey, D., Mcpherson, M., Roney, J., Stoové, M., Hellard, M. E., & Pedrana, A. (2019). Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study. The International Journal on Drug Policy, 72, 91–98. https://doi.org/10.1016/j.drugpo.2019.05.012
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2016). Combating hepatitis B and C to reach elimination by 2030. World Health Organization.
   Google Scholar
• Zeremski, M., Dimova, R. B., Zavala, R., Kritz, S., Lin, M., Smith, B. D., Zibbell, J. E., & Talal, A. H. (2014). Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance. Journal of Addiction Medicine, 8(4), 249–257. https://doi.org/10.1097/adm.0000000000000041
   PubMed Web of Science ®Google Scholar
• Zeremski, M., Zibbell, J. E., Martinez, A. D., Kritz, S., Smith, B. D., & Talal, A. H. (2013). Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World Journal of Gastroenterology, 19(44), 7846–7851. https://doi.org/10.3748/wjg.v19.i44.7846
   PubMed Web of Science ®Google Scholar
• Zhou, K., Fitzpatrick, T., Walsh, N., Kim, J. Y., Chou, R., Lackey, M., Scott, J., Lo, Y.-R., & Tucker, J. D. (2016). Interventions to optimise the care continuum for chronic viral hepatitis: A systematic review and meta-analyses. The Lancet. Infectious Diseases, 16(12), 1409–1422. https://doi.org/10.1016/S1473-3099(16)30208-0
   PubMed Web of Science ®Google Scholar